Mumbai, Sept. 22 -- Reported EBIDTA declined by 22.1% year-on-year (YoY) to Rs 45.2 crore while reported EBIDTA margin contracted by 800 basis points YoY to 21% in Q1 FY27.

Profit before tax in Q1 FY27 stood at Rs 17.5 crore, down by 60.9% from Rs 44.8 crore in Q1 FY26.

The company's net debt as on 30 June 2026 was Rs 398 crore. Post-IPO, the net debt stood at Rs 326 crore as on 20 September 2026.

Anil Satwani, chairman & managing director, Symbiotec Pharmalab, said: "Our first results as a listed company reflect a business with a steady growing core and two new growth engines for the future.

The API business - built over three decades of steroid chemistry depth and regulated-market presence - delivered steady revenue growth of 6% and...